Key result
Transaortic septal myectomy remains the gold standard for LVOTO in HCM with <1% mortality.
Surgical myectomy remains the gold standard treatment for symptomatic LVOT obstruction in HCM when pharmacologic therapy fails.
Answers are grounded in this paper and cite their sources.
Supports myectomy in experienced centers for obstructive HCM; leaves open need for randomized comparisons with alternatives.
Hypertrophic cardiomyopathy (HCM) is the most common congenital cardiac disease, affecting up to 1 in 200 individuals. When it causes left ventricular outflow tract (LVOT) obstruction, treatment is indicated to reduce symptoms and the risk of sudden cardiac death. Pharmacologic therapy is the first line treatment, however if it fails, surgical myectomy or percutaneous ablation of the hypertrophic myocardium are the standard therapies to eliminate subaortic obstruction. Both surgical myectomy and percutaneous ablation have been demonstrated as safe and effective treatments; however, myectomy is the gold standard with a significantly lower complication rate and more complete and longstanding reduction of LVOT obstruction.
No takes yet. Share an insight, caveat, or question.
Ralph‐Edwards et al. (2017) studied Hypertrophic obstructive cardiomyopathy. Transaortic septal myectomy was evaluated. Transaortic septal myectomy is the gold standard surgical treatment for left ventricular outflow tract obstruction in hypertrophic cardiomyopathy, with mortality typically less than 1% in dedicated centers.
Synapse has enriched 10 related papers. Consider them for comparative context: